Olanzapine Completed Phase 2 Trials for Alcohol Use Disorder (AUD) / Schizophrenia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03557931A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication
NCT00509067Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT02161718A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
NCT00259870SB-773812 Administered In Adults With Schizophrenia
NCT00073164Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia
NCT00149292Study of LY2140023 in Schizophrenia
NCT00265551Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia
NCT00316238A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
NCT00483964A Safety and Efficacy Study of Bacopa Monnieri and Nardostachys Jatamansi to Treat Schizophrenia
NCT00520923A Study for Patients With Schizophrenia
NCT00686998Phase IIA Study in Patients With Schizophrenia
NCT00728195An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
NCT00770744Efficacy of Lu 31-130 in Patients With Schizophrenia
NCT00816894D-serine Monotherapy for Schizophrenia
NCT00827918A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)
NCT00845026A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients
NCT01052103A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
NCT01234779A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
NCT01903837A Study of ALKS 3831 in Adults With Schizophrenia